Jazz Pharmaceuticals Q2 2026: Revenue Beats by $90M as Zepzelca Growth Offsets LAGOON Setback

summarizeSummary

Jazz Pharmaceuticals reported Q2 2026 revenue of $1.21B, beating estimates by $90M, with net income of $192.8M. Zepzelca's first-line maintenance launch drove 42% growth, but the LAGOON trial failure will lead to withdrawal of the second-line indication. Ziihera's first-line GEA sBLA has an August 25 PDUFA date.

check_boxKey Events · Earnings and Guidance · JAZZ

• Q2 Revenue Beat

  Total revenues of $1.21B exceeded consensus by $90M, driven by 42% growth in Zepzelca to $105.8M following its first-line maintenance launch.

• Net Income Swing

  Net income of $192.8M compared to a loss of $718.5M in Q2 2025, reflecting revenue growth and absence of prior-year Chimerix acquisition IPR&D charge.

• Zepzelca LAGOON Failure

  The Phase 3 LAGOON trial did not meet its primary OS endpoint; Jazz will submit a labeling supplement to remove the second-line SCLC indication, though the first-line maintenance indication is unaffected.

• Ziihera sBLA Accepted

  FDA accepted the sBLA for Ziihera in first-line HER2-positive GEA with Priority Review and a PDUFA target action date of August 25, 2026.

auto_awesomeAnalysis · JAZZ · Life Sciences

A strong second quarter saw revenue reach $1.21B, beating consensus by $90M, fueled by a 42% surge in Zepzelca following its first-line maintenance approval. Net income swung to $192.8M from a loss of $718.5M a year ago. However, the LAGOON confirmatory trial for Zepzelca in second-line SCLC failed to meet its primary OS endpoint, and the company will withdraw that indication — a setback that partially tempers the commercial momentum. On the pipeline front, the sBLA for Ziihera in first-line GEA was accepted with an August 25, 2026 PDUFA date, representing a near-term catalyst. The balance sheet strengthened with the repayment of $1.0B in 2026 Notes, though the 2030 Notes are now exchangeable, creating potential near-term dilution overhang.